Compare Stocks: SIBN, PLSE, ATRC, and TMDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRC AtriCure	$57.30 +0.8%	$52.05	$25.36 ▼ $61.70	$2.89B	1.24	1.47 million shs	799,283 shs
PLSE Pulse Biosciences	$46.32 -4.6%	$49.63	$12.56 ▼ $58.90	$3.44B	1.57	520,799 shs	439,994 shs
SIBN SiBone	$19.47 -1.1%	$18.92	$11.48 ▼ $21.89	$872.79M	0.66	590,988 shs	407,809 shs
TMDX TransMedics Group	$75.52 -4.6%	$85.89	$60.10 ▼ $156.00	$2.61B	1.94	756,949 shs	891,070 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRC AtriCure	+0.76%	+7.48%	+2.71%	+60.86%	+61.91%
PLSE Pulse Biosciences	-4.57%	-5.64%	-14.55%	+69.17%	+168.37%
SIBN SiBone	-1.07%	+1.94%	+4.12%	+9.88%	+27.59%
TMDX TransMedics Group	-4.57%	-6.85%	-12.04%	-0.63%	-32.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRC AtriCure	$57.30 +0.8%	$52.05	$25.36 ▼ $61.70	$2.89B	1.24	1.47 million shs	799,283 shs
PLSE Pulse Biosciences	$46.32 -4.6%	$49.63	$12.56 ▼ $58.90	$3.44B	1.57	520,799 shs	439,994 shs
SIBN SiBone	$19.47 -1.1%	$18.92	$11.48 ▼ $21.89	$872.79M	0.66	590,988 shs	407,809 shs
TMDX TransMedics Group	$75.52 -4.6%	$85.89	$60.10 ▼ $156.00	$2.61B	1.94	756,949 shs	891,070 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRC AtriCure	+0.76%	+7.48%	+2.71%	+60.86%	+61.91%
PLSE Pulse Biosciences	-4.57%	-5.64%	-14.55%	+69.17%	+168.37%
SIBN SiBone	-1.07%	+1.94%	+4.12%	+9.88%	+27.59%
TMDX TransMedics Group	-4.57%	-6.85%	-12.04%	-0.63%	-32.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRC AtriCure	2.58	Moderate Buy	$54.10	-5.58% Downside
PLSE Pulse Biosciences	2.86	Moderate Buy	$60.20	29.97% Upside
SIBN SiBone	2.71	Moderate Buy	$24.50	25.83% Upside
TMDX TransMedics Group	2.33	Hold	$115.60	53.07% Upside

Current Analyst Ratings Breakdown

Latest SIBN, PLSE, ATRC, and TMDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/14/2026	SIBN SiBone	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$23.00 ➝ $25.00
10/13/2026	PLSE Pulse Biosciences	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$55.00
10/13/2026	PLSE Pulse Biosciences	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$35.00 ➝ $60.00
10/13/2026	TMDX TransMedics Group	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$95.00 ➝ $94.00
10/12/2026	ATRC AtriCure	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$55.00 ➝ $63.00
10/8/2026	ATRC AtriCure	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
10/7/2026	TMDX TransMedics Group	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$120.00
10/6/2026	PLSE Pulse Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$43.00 ➝ $58.00
10/2/2026	ATRC AtriCure	Freedom Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
9/23/2026	PLSE Pulse Biosciences	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$70.00
9/23/2026	PLSE Pulse Biosciences	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$70.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRC AtriCure	$534.53M	5.45	$0.32 per share	181.70	$9.89 per share	5.79
PLSE Pulse Biosciences	$350K	9,369.87	N/A	N/A	$1.19 per share	38.92
SIBN SiBone	$213.60M	4.04	N/A	N/A	$4.09 per share	4.76
TMDX TransMedics Group	$668.47M	3.90	$3.75 per share	20.15	$13.79 per share	5.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRC AtriCure	-$11.45M	$0.21	247.26	127.33	N/A	1.85%	2.34%	1.77%	11/3/2026 (Confirmed)
PLSE Pulse Biosciences	-$72.78M	-$1.18	N/A	N/A	N/A	-6,755.78%	-94.42%	-79.96%	11/4/2026 (Estimated)
SIBN SiBone	-$18.90M	-$0.34	N/A	N/A	N/A	-6.85%	-8.23%	-6.07%	11/9/2026 (Estimated)
TMDX TransMedics Group	$190.29M	$3.89	19.41	33.42	1.09	22.69%	15.88%	5.95%	11/4/2026 (Estimated)

Latest SIBN, PLSE, ATRC, and TMDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	SIBN SiBone	-$0.13	N/A	N/A	N/A	$55.27 million	N/A
11/4/2026	Q3 2026	PLSE Pulse Biosciences	-$0.35	N/A	N/A	N/A	$0.52 million	N/A
11/4/2026	Q3 2026	TMDX TransMedics Group	$0.2976	N/A	N/A	N/A	$178.05 million	N/A
11/3/2026	Q3 2026	ATRC AtriCure	-$0.0427	N/A	N/A	N/A	$151.15 million	N/A
8/6/2026	Q2 2026	PLSE Pulse Biosciences	-$0.2933	-$0.36	-$0.0667	-$0.36	$0.53 million	$0.43 million
8/4/2026	Q2 2026	TMDX TransMedics Group	$0.4955	$0.44	-$0.0555	$0.41	$184.00 million	$189.95 million
8/3/2026	Q2 2026	SIBN SiBone	-$0.1495	-$0.09	+$0.0595	-$0.09	$55.34 million	$56.01 million
7/23/2026	Q2 2026	ATRC AtriCure	-$0.0017	$0.18	+$0.1817	$0.18	$151.80 million	$153.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRC AtriCure	N/A	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A	N/A
SIBN SiBone	N/A	N/A	N/A	N/A	N/A
TMDX TransMedics Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRC AtriCure	0.14	4.22	3.19
PLSE Pulse Biosciences	N/A	9.63	9.61
SIBN SiBone	0.20	9.15	7.55
TMDX TransMedics Group	1.62	6.62	6.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRC AtriCure	99.11%
PLSE Pulse Biosciences	76.95%
SIBN SiBone	98.11%
TMDX TransMedics Group	99.67%

Insider Ownership

Company	Insider Ownership
ATRC AtriCure	4.00%
PLSE Pulse Biosciences	74.00%
SIBN SiBone	4.00%
TMDX TransMedics Group	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRC AtriCure	1,350	50.87 million	48.83 million	Optionable
PLSE Pulse Biosciences	116	70.80 million	18.41 million	Optionable
SIBN SiBone	376	44.35 million	42.58 million	Optionable
TMDX TransMedics Group	898	34.56 million	32.18 million	Optionable

SIBN, PLSE, ATRC, and TMDX Headlines

Recent News About These Companies

iRhythm Technologies (NASDAQ:IRTC) versus TransMedics Group (NASDAQ:TMDX) Head-To-Head Comparison

4 hours ago | americanbankingnews.com

Canaccord Genuity Group Issues Pessimistic Forecast for TransMedics Group (NASDAQ:TMDX) Stock Price

October 15 at 1:36 AM | americanbankingnews.com

TransMedics Group (NASDAQ:TMDX) Stock Gets Price Target Trim from Canaccord Genuity Group

October 13 at 3:35 PM | marketbeat.com

Head-To-Head Survey: TransMedics Group (NASDAQ:TMDX) versus Cooper Companies (NASDAQ:COO)

October 12 at 3:58 AM | americanbankingnews.com

Barclays Initiates Coverage on TransMedics Group (NASDAQ:TMDX)

October 9, 2026 | americanbankingnews.com

Barclays initiates coverage of TransMedics Group at overweight

October 8, 2026 | msn.com

TransMedics Group consensus price target rises 10.91% to MX$1,984.96

October 8, 2026 | msn.com

41,109 TransMedics Group, Inc. $TMDX Shares Sold by Zevenbergen Capital Investments LLC

October 8, 2026 | marketbeat.com

TransMedics Group stock gets USD 120.00 target from Barclays

October 8, 2026 | ad-hoc-news.deA

TransMedics Group (NASDAQ:TMDX) Shares Climb 4.2% - Time to Buy?

October 7, 2026 | marketbeat.com

TransMedics Group (NASDAQ:TMDX) Now Covered by Analysts at Barclays

October 7, 2026 | marketbeat.com

TransMedics Group, Inc. $TMDX Shares Purchased by Congress Asset Management Co.

October 7, 2026 | marketbeat.com

TransMedics Group, Inc. (NASDAQ:TMDX) Stock Rated "Hold" by Sell-Side Analysts

October 5, 2026 | americanbankingnews.com

TransMedics Group, Inc. (NASDAQ:TMDX) Stock Has Average Price Target of $121.10 According to Brokerages

October 5, 2026 | marketbeat.com

TransMedics Group (TMDX) Stock Looks Below Fair Value On Earnings

October 4, 2026 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS)

October 3, 2026 | theglobeandmail.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: TransMedics Group (TMDX), Regeneron (REGN) and Tarsus Pharmaceuticals (TARS)

October 3, 2026 | theglobeandmail.com

TransMedics Group (TMDX) Could Be 19% Undervalued If Its Growth Narrative Holds

October 2, 2026 | finance.yahoo.com

TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?

September 29, 2026 | fool.com

TransMedics (TMDX)

September 28, 2026 | es.investing.com

TransMedics Offers An Attractive Entry Point, With Upside Potential Outweighing Risks

September 26, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN, PLSE, ATRC, and TMDX Company Descriptions

AtriCure NASDAQ:ATRC

$57.30 +0.43 (+0.76%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$57.85 +0.55 (+0.95%)

As of 08:17 AM Eastern

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Pulse Biosciences NASDAQ:PLSE

$46.32 -2.22 (-4.57%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$46.59 +0.27 (+0.58%)

As of 07:05 AM Eastern

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

SiBone NASDAQ:SIBN

$19.47 -0.21 (-1.07%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$18.83 -0.64 (-3.28%)

As of 07:59 AM Eastern

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

TransMedics Group NASDAQ:TMDX

$75.52 -3.62 (-4.57%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$75.00 -0.52 (-0.70%)

As of 08:19 AM Eastern

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SIBN, PLSE, ATRC, and TMDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SIBN, PLSE, ATRC, and TMDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SIBN, PLSE, ATRC, and TMDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN, PLSE, ATRC, and TMDX Company Descriptions

AtriCure NASDAQ:ATRC

Pulse Biosciences NASDAQ:PLSE

SiBone NASDAQ:SIBN

TransMedics Group NASDAQ:TMDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SIBN, PLSE, ATRC, and TMDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SIBN, PLSE, ATRC, and TMDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SIBN, PLSE, ATRC, and TMDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIBN, PLSE, ATRC, and TMDX Company Descriptions

AtriCure NASDAQ:ATRC

Pulse Biosciences NASDAQ:PLSE

SiBone NASDAQ:SIBN

TransMedics Group NASDAQ:TMDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools